Published in J Immunother on June 16, 2011
The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta (2011) 1.64
Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol In Vitro (2012) 0.84
Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71. Int J Endocrinol (2014) 0.78
Iron in multiple myeloma. Crit Rev Oncog (2013) 0.77
Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med (2014) 0.76
Identification of Tumor Antigen AF20 as Glycosylated Transferrin Receptor 1 in Complex with Heat Shock Protein 90 and/or Transporting ATPase. PLoS One (2016) 0.75
Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1. Mol Immunol (2015) 0.75
Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication. J Immunother (2015) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer (1976) 14.08
Avidin. Adv Protein Chem (1975) 10.27
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol (2006) 3.08
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res (2004) 2.77
The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol (2006) 2.18
The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol (1979) 2.11
Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev (2007) 2.11
The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol (1979) 2.02
Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol (2007) 1.69
Oral tolerance. Proc Natl Acad Sci U S A (1994) 1.35
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci U S A (1995) 1.32
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol (2008) 1.25
Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res (1990) 1.24
Establishment of five human myeloma cell lines. In Vitro Cell Dev Biol (1989) 1.23
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs (2010) 1.21
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res (2010) 1.20
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A (2002) 1.19
A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood (2003) 1.17
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res (2009) 1.09
Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica (2001) 1.06
Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol (2008) 1.05
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood (2006) 1.05
Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther (2007) 1.00
Development of an in vivo model of human multiple myeloma bone disease. Blood (1996) 1.00
Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program (2007) 1.00
Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Control Release (2007) 0.99
Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. J Nucl Med (1996) 0.96
Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol (2004) 0.95
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia (2005) 0.94
Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J Nucl Med (1996) 0.92
The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunol Immunother (2005) 0.92
A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther (2005) 0.91
Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs (2010) 0.90
Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin Cancer Res (1995) 0.90
The evolution and impact of therapy in multiple myeloma. Med Oncol (2010) 0.90
Antibody-cytokine fusion proteins for the therapy of cancer. Methods Mol Med (2005) 0.89
Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res (2007) 0.88
Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant (2008) 0.87
Characterization and phenotypic analysis of differentiating CD34+ human bone marrow cells in liquid culture. Eur J Haematol (1997) 0.87
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res (2009) 0.87
Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J Oncol (2010) 0.83
Defective killing of Candida albicans hyphae by neutrophils from beige mice. J Infect Dis (1995) 0.81
Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties. Immunology (1994) 0.78
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol (2006) 3.08
The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol (2006) 2.18
Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res (2003) 2.01
Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer (2010) 1.75
Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol (2004) 1.73
The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta (2011) 1.64
Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol (2011) 1.62
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res (2010) 1.59
The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS (2015) 1.53
Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS (2015) 1.47
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res (2004) 1.46
The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol (2009) 1.46
Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res (2009) 1.45
Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma. Leuk Lymphoma (2014) 1.44
Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS (2011) 1.42
Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol (2006) 1.40
Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res (2014) 1.39
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res (2007) 1.39
Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol (2005) 1.37
Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res (2009) 1.37
Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol (2004) 1.35
Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res (2005) 1.32
Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene (2004) 1.30
Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol (2003) 1.30
Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Mol Immunol (2006) 1.28
Propulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks. Proc Natl Acad Sci U S A (2009) 1.26
NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol (2008) 1.25
Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res (2004) 1.25
HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res (2010) 1.24
Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol (2006) 1.23
Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res (2007) 1.23
Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol (2007) 1.21
Targeting aurora kinases as therapy in multiple myeloma. Blood (2007) 1.19
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A (2002) 1.19
IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood (2003) 1.18
Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res (2011) 1.16
Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol (2007) 1.15
Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res (2007) 1.15
Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol (2003) 1.14
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis. AIDS (2007) 1.14
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol (2008) 1.13
Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J Control Release (2007) 1.13
Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol (2006) 1.13
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther (2004) 1.12
Nitric oxide donors: novel cancer therapeutics (review). Int J Oncol (2008) 1.12
Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol (2007) 1.12
CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One (2010) 1.09
Comment on "characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study". J Acquir Immune Defic Syndr (2014) 1.09
Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther (2003) 1.08
Alternative splicing of Slo channel gene programmed by estrogen, progesterone and pregnancy. FEBS Lett (2005) 1.08
Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res (2012) 1.08
Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene (2005) 1.07
Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. J Proteome Res (2010) 1.07
Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol (2006) 1.06
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate (2002) 1.06
Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene (2004) 1.06
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol (2012) 1.06
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood (2006) 1.05
Distribution of immune cell subsets and cytokine-producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: influence of HIV-1 coinfection. Diagn Mol Pathol (2005) 1.04
Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle (2010) 1.04
Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma. AIDS Res Treat (2010) 1.01
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res (2009) 1.01
Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev (2012) 1.01
Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther (2007) 1.00
A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med (2009) 1.00
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther (2007) 1.00
Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab (2013) 1.00
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother (2008) 0.99
Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Control Release (2007) 0.99
Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation (2004) 0.99
Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res (2009) 0.97
TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk (2012) 0.96
Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clin Cancer Res (2012) 0.96
The NO TRAIL to YES TRAIL in cancer therapy (review). Int J Oncol (2007) 0.96
Retracted Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res (2010) 0.95
Temporal stability of serum concentrations of cytokines and soluble receptors measured across two years in low-risk HIV-seronegative men. Cancer Epidemiol Biomarkers Prev (2013) 0.95
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol (2006) 0.95
Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men. Drug Alcohol Depend (2008) 0.95
Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des (2009) 0.94
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer (2011) 0.94
Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. Adv Cancer Res (2007) 0.94
Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide (2008) 0.94
Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle (2011) 0.94